Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDORA: EF190 in Moderate Acne Vulgaris
NCT06905210Phase 3Recruiting
- Sponsor
- Eurofarma
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyproterone, ethinyl estradiol in acne vulgaris, sponsored by Eurofarma. Started Aug 2026; status: recruiting.
02
Drugs
cyproteroneethinyl estradiol
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06905210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905210.